A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.

TitleA subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.
Publication TypeJournal Article
Year of Publication2013
AuthorsZhang L, Yang J, Cai J, Song X, Deng J, Huang X, Chen D, Yang M, Wery J-P, Li S, Wu A, Li Z, Li Z, Liu Y, Chen Y, Li Q, Ji J
JournalScientific reports
Volume3
Pagination2992
Date Published2013
Abstract

A preclinical trial identified 4 of 20 (20%) gastric cancer (GC) patient-derived xenografts responded to cetuximab. Genome-wide profiling and additional investigations revealed that high EGFR mRNA expression and immunohistochemistry score (3+) are associated with tumor growth inhibition. Furthermore, EGFR amplification were observed in 2/4 (50%) responders with average copy number 5.8 and >15 respectively. Our data suggest that a GC subtype with EGFR amplification and overexpression benefit from cetuximab treatment.

DOI10.1371/journal.pntd.0002484
Alternate JournalSci Rep